Dr. Olsen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12697 E 51st St
Tulsa, OK 74146Phone+1 918-505-3200Fax+1 918-505-3253
Education & Training
- University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1995 - 1998
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1995
- University of Wisconsin School of Medicine & Public HealthClass of 1992
Certifications & Licensure
- OK State Medical License 1998 - 2025
- WI State Medical License 1996 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Publications & Presentations
PubMed
- 44 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Nicholas J Vogelzang, Mark R Olsen, Joshua J McFarlane, Edward Arrowsmith, Todd M Bauer
Clinical Genitourinary Cancer. 2020-12-01 - 26 citationsSafety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent
Cancer. 2021-11-16 - 16 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
Clinical Genitourinary Cancer. 2020-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: